Lysophosphatidylcholine 18:2 exacerbates Th17-dominant inflammation in obese asthma
Our findings highlight LPC 18:2 as a potential metabolic regulator that may link obesity-associated lipid disturbances to pathological Th17-skewed immune responses. Modulation of LPC 18:2-related pathways may therefore represent a novel therapeutic strategy for this asthma phenotype.
Authors
- Tingting Hu
- Ying Shang
- Abudureyimujiang Aili (ORCID: https://orcid.org/0000-0002-6893-5561)
- Chang Chen (ORCID: https://orcid.org/0009-0008-6416-7172)
- Zemin Li
- Huan liu
- Liting Cao
- Yingying Ge
Institutions
- Peking University (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- Lipids in Health and Disease
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1186/s12944-026-02907-4
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00